Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Acadia Pharmaceuticals Inc shares valued at $41,560 were sold by GAROFALO ELIZABETH A. on Sep 02 ’25. At $25.98 per share, GAROFALO ELIZABETH A. sold 1,600 shares. The insider’s holdings dropped to 25,382 shares worth approximately $0.65 million following the completion of this transaction.
Also, Schneyer Mark C. sold 22,000 shares, netting a total of over 554,024 in proceeds. Following the sale of shares at $25.18 each, the insider now holds 40,130 shares.
Before that, Schneyer Mark C. had added 22,000 shares to its account. In a trade valued at $557,260, the Officer bought Acadia Pharmaceuticals Inc shares for $25.33 each.
As published in a research note from Deutsche Bank on May 21, 2025, Acadia Pharmaceuticals Inc [ACAD] has been rated up from a Hold to a Buy and the price target has been revised to $35. Analysts at Deutsche Bank started covering the stock with ‘”a Hold”‘ outlook in a report released in mid February. As of January 03, 2025, Guggenheim has decreased its “Buy” rating to a “Neutral” for ACAD.
Analyzing ACAD Stock Performance
On last trading session, Acadia Pharmaceuticals Inc [NASDAQ: ACAD] rose 0.12% to $25.72. The stock’s lowest price that day was $25.36, but it reached a high of $26.09 in the same session. Over the course of the year, Acadia Pharmaceuticals Inc shares have jumped approximately 57.60%. Shares of the company reached a 52-week high of $26.65 on 08/28/25 and a 52-week low of $13.40 on 04/09/25.
Support And Resistance Levels for Acadia Pharmaceuticals Inc (ACAD)
According to the 24-hour chart, there is a support level at 25.36, which, if violated, would cause prices to drop to 24.99. In the upper region, resistance lies at 26.09. The next price resistance is at 26.45. RSI (Relative Strength Index) is 59.41 on the 14-day chart, showing neutral technical sentiment.
Is Acadia Pharmaceuticals Inc subject to short interest?
Stocks of Acadia Pharmaceuticals Inc saw a sharp steep in short interest on 2025-08-15 dropping by -1.49 million shares to 9.98 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 11.48 million shares. A decline of -14.97% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.43 of the overall float, the days-to-cover ratio (short ratio) decline to 5.43.
Which companies own the most shares of Acadia Pharmaceuticals Inc (ACAD)?
In terms of Acadia Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 30 in the next 12 months, up nearly 16.78% from the previous closing price of $25.69. Analysts anticipate Acadia Pharmaceuticals Inc stock to reach 36 by 2025, with the lowest price target being 22. In spite of this, 16 analysts ranked Acadia Pharmaceuticals Inc stock as Buy at the end of 2025. On August 07, 2024, Morgan Stanley assigned a price target of “an Equal-weight” to the stock and downgraded coverage with a $20.
